OBJETIVO: Estudar a distribuição dos ramos da artéria esplênica dirigidos ao baço aplicado ao estudo radiológico da sua distribuição intraparenquimatosa, visando à utilização destes conhecimentos na esplenectomia parcial. MÉTODOS: no estudo macroscópico, foram utilizados 60 baços humanos dos quais as artérias esplênicas foram dissecadas desde sua origem para visualizar a divisão terminal e os ramos dirigidos ao baço. Realizaram-se as medidas da distância entre a face visceral do baço e a divisão terminal da artéria esplênica e da emergência dos ramos polares. No estudo radiológico, utilizaram-se 30 baços humanos nos quais se injetou contraste nas artérias esplênicas para realizar as arteriografias e estudar a divisão terminal e ramos polares. RESULTADOS: 93,34% dos baços apresentaram bifurcação como padrão de divisão terminal e 6,66% trifurcação. Identificaram-se ramos colaterais secundários e terciários tendo como freqüência relativa de 10% para o tipo I, 17% para o tipo II e 8,33% para ambas. A distância entre a face visceral do baço e a divisão terminal foi, em média, 2,89cm e para a emergência da artéria polar tipo I foi 4,85cm e 2,39cm para a tipo II. Nas 30 arteriografias realizadas, fez-se um estudo da divisão terminal no qual se observou bifurcação em 90% dos baços e trifurcação em 10%, além da presença de artéria polar tipo I em 16% e tipo II em 20%. CONCLUSÃO: a artéria esplênica apresenta divisão terminal do tipo bifurcação que pode ser visualizada arteriograficamente. Destaca-se a existência de segmentação arterial independente na quase totalidade dos casos (98%), semelhantes nas faces visceral e diafragmática do baço. A esplenectomia parcial é anatômica e torna-se factível o emprego de métodos radiológicos no tratamento conservador das lesões esplênicas.
HCV infection is highly prevalent among kidney transplant (KT) recipients. The natural history and management of these patients are controversial. We sought to assess the diagnostic value of noninvasive markers of liver fibrosis in KT HCV-infected patients. This cross-sectional study included 102 KT individuals with positive HCV-RNA. Bivariate and multivariate analyses were used to identify variables associated with significant fibrosis (METAVIR > or = F2). Significant fibrosis was observed in 20 patients (20%). Time after transplantation, AST level, and platelet count were identified as independent predictors of significant fibrosis. Based on the regression model, a simplified index was devised. The AUROC for the TX-3 model was 0.867 +/- 0.081 (0.909, when adjusted by DANA). Values < or =4.0 of TX-3 showed a NPV of 97% and scores >9.6 exhibited a PPV of 71%. If biopsy indication was restricted to scores in the intermediate range of TX-3, this could have been correctly avoided in 68% of cases. The APRI score provided a correct diagnosis in only 47 individuals (46%) and exhibited lower diagnostic indices for both cutoffs, as compared to the TX-3 index. Comparison of AUROCs showed a trend towards superior diagnostic accuracy for TX-3 over APRI, although the difference between AUROCs did not reach statistical significance (0.867 +/- 0.053 vs 0.762 +/- 0.066, respectively, P = 0.064). In conclusion, significant liver fibrosis can be reliably predicted in KT HCV-infected subjects by simple and widely available parameters. If additional studies confirm our results, this model might obviate the requirement for a liver biopsy in a significant proportion of those patients.
The left ventricular noncompaction is a congenital cardiomyopathy characterized by the presence of abnormal trabeculations in the left ventricle. The present study describes the case of a 14-year-old female Para athlete, who plays goalball. She was asymptomatic, with history of congenital nystagmus and mild visual impairment, who presented nonspecific electrocardiographic abnormalities during pre-competition screening. Cardiac magnetic resonance imaging showed left ventricular non-compaction (non-compacted to compacted layer ratio equal to 2.5) and mild biventricular systolic dysfunction. Initially, the patient was excluded from sports participation and clinical follow-up was performed every three months. Patient remained asymptomatic during the one-year follow-up, with no history of unexplained syncope, marked impairment of systolic function or significant ventricular arrhythmias at the exercise stress test. Finally, she was released for competitive goalball participation and clinical follow-up was continued every 6 months. There is no consensus regarding the eligibility criteria for sports participation in cases of left ventricular non-compaction. Thus, it is prudent to individualize the decision regarding practice of sports, as well as to consider participation in competitive sports for asymptomatic individuals and with no disease repercussions.
CONTEXT AND OBJECTIVE: The prevalence of post-renal transplant anemia (PTA) reported in the literature is variable and several factors contribute towards its pathophysiology. This study aimed to investigate the prevalence of PTA, its associated risk factors and the impact of therapy without steroids. DESIGN AND SETTING: Retrospective cohort study in a renal transplantation unit at a tertiary hospital. METHODS: Anemia was defined as hemoglobin (Hb) < 12 g/dl in female adult recipients and < 13 g/dl in males. Donor and recipient age and gender, type of donor, creatinine, delayed graft function, acute rejection, use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) and therapy without steroids were investigated as risk factors for PTA through multivariate logistical regression analysis. RESULTS: Evaluations were performed on 258 recipients (mean age: 38.8 years; 60.5% males; 35.7% did not receive steroids). Anemia was diagnosed in 38% of the patients (at the sixth month, M6), 28% (M12), 32% (M24) and 45% (at last follow up). Donor age > 50 years was associated with greater risks of PTA at M6 (odds ratio (OR) = 4.68) and M24 (OR = 6.57), as well as with therapy without steroids at M6 (OR = 2.96). Delayed graft function was independently associated with PTA at M6 (OR = 3.66) and M12 (OR = 2.85). CONCLUSION:The lowest prevalence of PTA was observed between M9 and M24 after renal transplantation. Delayed graft function, donor age and therapy without steroids were the most important factors associated with PTA. RESUMO CONTEXTO E OBJETIVO:A prevalência de anemia pós-transplante renal (APR) relatada na literatura é variável e vários fatores contribuem para sua fisiopatologia. Este estudo objetivou investigar a prevalência de APR, os fatores de risco associados e o impacto da terapia sem esteroides. TIPO DE ESTUDO E LOCAL: Estudo de coorte retrospectivo em unidade de transplante renal em hospital terciário. MÉTODOS: Anemia foi definida como hemoglobina (Hb) < 12 g/dl em receptores adultos do sexo feminino e < 13 g/dl no masculino. Idade e gênero do doador e do receptor, tipo de doador, creatinina, função retardada do enxerto (FRE), rejeição aguda, uso de inibidores da enzima conversora da angiotensina (IECA)/bloqueadores dos receptores da angiotensina (BRA) e terapia sem esteroides foram investigados como fatores de risco para APR em análise de regressão logística multivariada. RESULTADOS: Duzentos e cinquenta e oito receptores foram avaliados (idade média: 38,8 anos; 60,5% homens; 35,7% em terapia sem esteroides). Anemia foi diagnosticada em 38% no sexto mês (M6), 28% (M12), 32% (M24) e em 45% dos pacientes na última data de acompanhamento. Idade do doador > 50 anos associou-se a maior risco de APR aos 6 (odds ratio, OR = 4,68) e 24 meses (OR = 6,57), bem como terapia sem esteroides aos 6 meses (OR = 2,96). FRE associou-se independentemente com APR aos 6 (OR = 3,66) e 12 meses (OR = 2,85). CONCLUSÃO: A menor prevalência de APR foi observada entre 9 e 24 meses pós-transplante...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.